Axsome Therapeutics, Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase II trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation treatment. The company was incorporated in 2012 and is based in New York, New York.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-01-21$189.10 RISE2026-03-12$154.12 PEAK2026-05-22$235.97 121d | -18.5% 50d | Missed | Missed | — | — | +53.1% 71d | Missed |
DROP2025-03-24$129.17 RISE2025-07-28$100.39 PEAK2025-10-20$131.60 210d | -22.3% 126d | Missed | Missed | — | — | +31.1% 84d | Missed |
DROP2025-02-21$137.75 RISE2025-06-20$100.69 PEAK2025-09-08$129.29 199d | -26.9% 119d | Missed | Missed | — | — | +28.4% 80d | Missed |
DROP2025-02-21$137.75 RISE2025-04-10$95.65 PEAK2025-05-05$116.49 73d | -30.6% 48d | Missed | Missed | — | — | +21.8% 25d | Missed |
DROP2024-12-03$100.49 RISE2025-01-10$80.05 PEAK2025-02-21$137.75 80d | -20.3% 38d | Missed | Missed | — | — | +72.1% 42d | Missed |
DROP2024-02-12$97.64 RISE2024-06-11$71.07 PEAK2024-09-04$95.56 205d | -27.2% 120d | Missed | Missed | — | — | +34.5% 85d | Missed |
DROP2024-02-12$97.64 RISE2024-04-18$65.72 PEAK2024-07-16$84.95 155d | -32.7% 66d | Missed | Missed | — | — | +29.3% 89d | Missed |
DROP2024-02-12$97.64 RISE2024-03-12$69.39 PEAK2024-03-21$80.86 38d | -28.9% 29d | Missed | Missed | — | — | +16.5% 9d | Missed |
DROP2023-09-12$82.21 RISE2023-11-10$57.42 PEAK2024-02-08$95.68 149d | -30.2% 59d | Missed | Missed | — | — | +66.6% 90d | Missed |
DROP2023-06-22$90.35 RISE2023-08-17$69.25 PEAK2023-09-12$82.21 82d | -23.4% 56d | Missed | Missed | — | — | +18.7% 26d | Missed |
DROP2023-06-22$90.35 RISE2023-07-03$70.24 PEAK2023-09-12$82.21 82d | -22.3% 11d | Missed | Missed | — | — | +17.0% 71d | Missed |
DROP2023-05-10$80.22 RISE2023-05-25$68.09 PEAK2023-06-22$90.35 43d | -15.1% 15d | Missed | Missed | — | — | +32.7% 28d | Missed |
DROP2022-12-14$79.72 RISE2023-03-10$58.39 PEAK2023-05-10$80.22 147d | -26.8% 86d | Missed | Missed | — | — | +37.4% 61d | Missed |
DROP2022-12-14$79.72 RISE2023-01-11$62.16 PEAK2023-01-31$75.00 48d | -22.0% 28d | Missed | Missed | — | — | +20.7% 20d | Missed |
DROP2022-08-25$69.85 RISE2022-10-24$39.94 PEAK2022-12-14$79.72 111d | -42.8% 60d | Missed | Missed | — | — | +99.6% 51d | Missed |
1–15 / 26 1 / 2 | |||||||
Axsome Therapeutics has received FDA approval for Auvelity, the first non-psychotic agitation treatment for Alzheimerâs disease. Click for my ASXM stock update.
Axsome Therapeutics (NASDAQ:AXSM) executives said the company is preparing for a June launch of AUVELITY in Alzheimer’s disease agitation while continuing to expand its push in major depressive disorder, citing broad payer access, a larger sales force and what they described as a differentiated clin
Axsome Therapeutics, Inc. (AXSM) Bank of America Global Healthcare Conference 2026 May 12, 2026 11:40 AM EDTCompany ParticipantsMark Jacobson - Chief...
Presentation Operator MessageOperator We are introducing Axome, Our next company presenter. We've got Mark Jacobson. Chief Operating Officer; and Nick Pizzie, Chief Financial Officer. So gentlemen,...
Truth be told, a survey of leading biotech stocks currently in the IBD 50 actually accentuates the importance of using both daily and weekly charts in the same manner as, say, the mega-cap leaders such as Sandisk, Micron Technology, and Western Digital in the data storage segment. The concept also applies to other tech leaders such as Marvell Technology in application-specific integrated circuits, and Ciena, a fiber-optic data networking company. Marvell carries a $140 billion market cap, and Ciena is valued at $76 billion.
Health officials explored restricting specific antidepressants among SSRI drugs-sources
The old healthcare model is breaking down.
Axsome Therapeutics: Stock Performance Snapshot Axsome Therapeutics (AXSM) stock has attracted investor attention after a strong run, with the share price at US$222.63 and total return figures over the past year and past 3 months drawing closer scrutiny. See our latest analysis for Axsome Therapeutics. The recent 7 day share price return of 21.03% and 30 day share price return of 31.16%, alongside a 1 year total shareholder return of 100.82%, point to momentum that has built over time rather...
The Street’s updated fair value estimate for Axsome Therapeutics has shifted from US$223.99 to US$266.94, signaling a different view on potential upside built into current models. That reset is tied to fresh analyst work on Auvelity, the AXS-05 PDUFA decision for Alzheimer’s disease agitation, and how quickly the broader pipeline and indications might translate into cash generation. Below, you will see what is driving these shifting price targets and how to track the story as new data and...
NEW YORK, May 07, 2026 -- Axsome Therapeutics, Inc. , a biopharmaceutical company leading a new era in the treatment of central nervous system disorders, today announced its support for Mental...
Wondering whether Axsome Therapeutics at US$222.63 is starting to look expensive or if the price is still catching up to its story? This article breaks down what that current level might mean for value focused investors. The stock has moved sharply in recent periods, with returns of 21.0% over 7 days, 31.2% over 30 days, 24.6% year to date, 100.8% over 1 year, 177.5% over 3 years and 290.5% over 5 years. These moves are set against a backdrop of ongoing interest in pharmaceuticals and...
Axsome posts a wider Q1 loss but revenues jump 57%, driven by strong Auvelity and Sunosi sales.
These relatively small biotechs have recent catalysts that haven't yet been fully priced into their stocks.
Morgan Stanley analyst Sean Laaman maintains Axsome Therapeutics (NASDAQ:AXSM) with a Equal-Weight and raises the price target from $217 to $242.
RBC Capital analyst Leonid Timashev maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and raises the price target from $242 to $302.
Wells Fargo analyst Benjamin Burnett maintains Axsome Therapeutics (NASDAQ:AXSM) with a Overweight and raises the price target from $225 to $255.
Guggenheim analyst Yatin Suneja maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises the price target from $245 to $260.
Mizuho analyst Graig Suvannavejh maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and raises the price target from $228 to $310.
Baird analyst Joel Beatty maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and raises the price target from $241 to $246.
NEW YORK, May 05, 2026 -- Axsome Therapeutics, Inc. , a biopharmaceutical company leading a new era in the treatment of central nervous system disorders, today announced that it will participate...
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| AXSM | +13.53% | +40.93% | +28.38% | +122.97% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +10.56% | +46.65% | +31.83% | +110.29% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| FidelityFMR | fundamental | 1.57M | $264.85M | 0.01% | Added+32.6% | 2026-03-31 |
| Wellington | fundamental | 1.15M | $193.58M | 0.04% | Trimmed-6.2% | 2026-03-31 |
| StateStreet | passive | 986.8K | $166.79M | 0.01% | Added+3.0% | 2026-03-31 |
| DEShaw | quant | 603.5K | $102.00M | 0.06% | Added+9.9% | 2026-03-31 |
| Citadel | multi-strat | 424.8K | $71.79M | 0.09% | Added+2259.9% | 2026-03-31 |
| TwoSigma | quant | 322.8K | $54.56M | 0.04% | Added+121.7% | 2026-03-31 |
| RenTech | quant | 164.3K | $27.77M | 0.04% | Trimmed-3.4% | 2026-03-31 |
| Bridgewater | macro | 57.0K | $9.63M | 0.04% | Added+20.0% | 2026-03-31 |
| TRowePrice | fundamental | 1.32M | $222.61K | 0.03% | Trimmed-12.8% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-03upcoming | -0.82 | — | — |
| 2026-05-04 | -0.86 | -1.26 | -46.03% |
| 2026-02-23 | -0.73 | -0.56 | +23.63% |
| 2025-11-03 | -0.90 | -0.94 | -4.19% |
| 2025-08-04 | -1.09 | -0.97 | +10.75% |
| 2025-05-05 | -1.35 | -1.22 | +9.51% |
| 2025-02-18 | -1.01 | -1.54 | -52.55% |
| 2024-11-12 | -1.39 | -1.34 | +3.49% |
| 2024-08-05 | -1.33 | -1.67 | -25.84% |
| 2024-05-06 | -1.22 | -1.44 | -17.65% |
| 2024-02-20 | -1.19 | -2.08 | -74.83% |
| 2023-11-06 | -1.19 | -1.32 | -10.92% |
| 2023-08-07 | -1.20 | -1.54 | -28.81% |
| 2023-05-09 | -0.72 | -0.26 | +64.09% |
| 2023-02-27 | -1.14 | -1.41 | -24.05% |
| 2022-11-07 | -1.10 | -1.07 | +2.81% |